LONDON, March 4 (Reuters) - Sanofi-Aventis's experimental chemotherapy drug Jevtana increases survival by 30 percent in men with prostate cancer whose tumours no longer respond to standard treatment, ...

The FINANCIAL — Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced on July 19 that Jevtana (cabazitaxel) Injection is now available in the United States for patients with metastatic ...

Jevtana is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a ...

MELBOURNE, Australia, Sept. 12, 2022 /PRNewswire/ -- Cabazitaxel (Jevtana, Sanofi) is a market leading chemotherapy for the treatment of advanced prostate cancer (mCRPC). Developed by Australian ...

Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel. This guidance does not cover the use of cabazitaxel for ...

After years of back-and-forth with several generics makers, Sanofi came out on top in its latest Jevtana litigation, successfully blocking generic competition to the prostate cancer drug from Novartis ...

When other therapies have failed, patients with metastatic prostate cancer who were treated with Jevtana (cabazitaxel) in the third-line setting experienced a toxicity profile similar to that of ...

LONDON (Reuters) - Britain's healthcare cost watchdog NICE has recommended that a new prostate cancer pill from Medivation and Astellas should be used on the state health service. The draft guidance ...